Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients

Angelo Paradiso, Stefania Tommasi, Anna Barletta, Bernardo Leone, Juan Lacava, Carlos Vellejo, Angela Labriola, Francesco Marzullo, Rosanna Altieri, Francesco Schittulli, Mario De Lena

Research output: Contribution to journalArticlepeer-review


p53 mutations have been reported to correlate with prognosis and response to therapy in patients with different tumor types. However, although p53 status is related to the primary tumor aggressiveness, an association between its expression and specific metastatic pattern has not yet been investigated. We immunohistochemically analyzed p53 (Pab1801) and ki67 (mib1) primary tumor expression in a series of advanced breast cancer patients presenting a selected pattern of distant metastases at the time of first diagnosis. Forty-eight percent of the overall series was classified as p53 positive while 22% as mib1 positive tumors. The overall agreement between p53 and mib1 expression was statistically significant (p = 0.03). While mib1 primary tumor expression did not show any association with the type of metastasis, p53 positivity was significantly higher in patients with soft tissue metastasis than in patients with bone or viscera metastasis (p = 0.002). No association with the probability of clinical response or different overall survival was found for patients with different p53 or mib1 status either in the overall series of patients or in subgroups of cases with different sites of distant metastasis.

Original languageEnglish
Pages (from-to)4523-4528
Number of pages6
JournalAnticancer Research
Issue number5 C
Publication statusPublished - 1999


  • Breast cancer
  • Metastasis
  • mib1
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients'. Together they form a unique fingerprint.

Cite this